# KLOW Peptide Dosage — Component-Level Research Context and Pharmacokinetics > KLOW peptide dosage research: the 80 mg vial composition, component half-lives, the inherent pharmacokinetic mismatch, and routes studied — all research-context only, no human dosing recommendation. No validated human dosing protocol exists for the blend. What follows is the component-level pharmacokinetic record — logged as a mismatch specification. ## Before the details There is no validated human dose for KLOW peptide as a blend — no clinical trial has tested it, so no dose range has ever been measured or approved. What exists is a research-vial convention: 80 mg total, split roughly 50/10/10/10 mg across the four components. The more significant finding from a pharmacokinetics perspective is that the four components clear the body at very different speeds. KPV and GHK-Cu are small tripeptides that break down quickly; BPC-157 is a larger peptide with a short but measurably longer presence; TB-500 is a medium-sized fragment whose behavior in humans has not been formally measured. Giving all four in one vial means the exposures will not overlap evenly — the fast-clearing peptides peak and fall before the slower ones have run their course. This is a property of the blend's design, not a flaw in any single component. It is documented here because it is the most structurally important feature of KLOW as a co-formulation. ## KLOW peptide dosage — the canonical vial composition The most widely listed research-vial composition across independent compounders is: - GHK-Cu: 50 mg (62.5% by mass) - BPC-157: 10 mg (12.5% by mass) - TB-500: 10 mg (12.5% by mass) - KPV: 10 mg (12.5% by mass) - **Total: 80 mg** This is a research formulation convention, not a validated clinical dose. No pharmacopeial specification or FDA-approved product exists for this combination. Reconstitution is typically with bacteriostatic water for laboratory handling; the lyophilized blend is refrigerated post-reconstitution. Component-level doses administered in the published research literature are listed below for reference. These are the doses used in specific experiments with specific species by specific routes — they are not recommendations for human administration. ## KLOW dosage — component pharmacokinetics: the mismatch table The four KLOW components have markedly different reported pharmacokinetic profiles. This is the central structural limitation of co-formulating them at a fixed dose ratio. **KPV (MW 342.44 Da, CAS 67727-97-3).** The smallest peptide in the blend. PepT1-mediated transport into cells suggests rapid uptake and likely fast degradation; no validated half-life in plasma has been published in a dedicated KPV PK study. Based on di/tripeptide PK generally, clearance is expected to be rapid (minutes to low-single-digit hours). **GHK-Cu (MW 402.92 Da, CAS 89030-95-5).** Rat plasma HPLC data show free GHK is rapidly degraded to the dipeptide histidyl-lysine (HK) after intravenous administration, with detection limits of 50 ng/mL for GHK and 15 ng/mL for HK [8]. No validated human half-life exists. The copper moiety may behave differently from the peptide backbone and is not fully characterized in the context of rapid GHK degradation. **BPC-157 (MW 1419.53 Da, CAS 137525-51-0).** An elimination half-life of under approximately 30 minutes has been reported in rat pharmacokinetic studies, making it the formally-characterized PK anchor for the blend; it clears faster than most peptides of its size suggest. At 2025 IV human doses of 10–20 mg in two adults, BPC-157 was detectable without adverse events [6], but no human half-life has been formally published. **TB-500 (Ac-LKKTETQ, MW 889.02 Da).** Detection in equine plasma/urine at LOD 0.01–0.02 ng/mL has been reported in a doping-control context [9], establishing an analytical presence window, but no validated human or rat PK half-life study has been published for the TB-500 fragment specifically. **The mismatch.** A single co-formulated dose cannot hold KPV, GHK-Cu, BPC-157, and TB-500 at matched tissue exposures simultaneously. The two tripeptides clear faster than the BPC-157; TB-500's clearance relative to the others is uncharacterized. Whether timed or split dosing of the components would provide more concordant exposures has not been studied for KLOW. ## KLOW peptide dosage and frequency — research context only Doses recorded in the component literature: - **KPV:** 10 nM in human intestinal epithelial cell cultures; 100 microM in drinking water in murine colitis models [3]. No human dose. - **GHK-Cu:** Low-nanomolar concentrations in cell culture (transcriptomic studies [5]); topical formulations in placebo-controlled cosmetic trials [4]; 0.5 mg/cm^3 in liposomal formulations for skin delivery [13]. No approved systemic human dose. - **BPC-157:** 10 microg, 10 ng, or 10 pg per rat IP in the Achilles tendon model [2]; 10–20 mg IV in 250 cc saline in the 2025 human safety pilot [6] — a safety tolerability assessment in two adults, not a dosing protocol. - **TB-500 / Tbeta4:** 10 pg sufficed to stimulate keratinocyte migration in vitro; topical and IP routes were studied in rat wound models [1]. No validated human dose for the TB-500 fragment. No human KLOW dose recommendation exists in the peer-reviewed literature. The component doses above are recorded for research transparency, not as a guide for administration. ## Routes studied in the component literature Component studies have used: - **Subcutaneous / intraperitoneal injection** (BPC-157, TB-500 / Tbeta4 rodent studies) - **Intravenous infusion** (BPC-157 human pilot [6]; GHK rat plasma PK [8]) - **Oral / targeted delivery** (KPV in DSS mouse colitis [3, 11, 15]; BPC-157 oral in some rodent work) - **Topical** (GHK-Cu cosmetic studies [4, 10, 13]; Tbeta4 wound topical application [1]) The KLOW research vial is lyophilized for subcutaneous injection in research settings. The route-efficacy data supporting different injection sites come from single-component studies, not from the blend. ## Stability and reconstitution notes Lyophilized peptide blends are typically reconstituted with bacteriostatic water and refrigerated after reconstitution. A theoretical compatibility consideration for KLOW specifically: copper(II) in GHK-Cu can participate in redox chemistry, and co-dissolving it with three other peptides in one vial raises a theoretical oxidation or compatibility concern. This has not been formally characterized for the KLOW mixture; it is noted here because the chemistry is established and the interaction in the specific blend is not. --- A cold spec-sheet record of the four-peptide KLOW blend — each component logged to its own study dossier, the combination-trial field left blank because none exists, and no clinic behind the chassis.